Why Methotrexate Is Still the Anchor Drug in Rheumatoid Arthritis

Methotrexate remains the anchor drug for rheumatoid arthritis because the 2021 American College of Rheumatology (ACR) guideline was built to reward efficacy, long-term safety, and durability under formal evidence grading, and methotrexate keeps winning that comparison. For most patients starting treatment, the guideline strongly recommends methotrexate alone ahead of other conventional pills and ahead of biologics. It also strongly favors a treat-to-target strategy and strongly advises against routine longer-term steroids. Reading the guideline well means reading two things at once: what it recommends, and how confident it is in each call.

How the guideline is actually built

The 2021 ACR guideline, published by Fraenkel and colleagues in Arthritis and Rheumatology, contains 44 recommendations. Only seven are labeled strong; the other 37 are conditional. That ratio is the first thing to notice, and it is a feature rather than a flaw.

The panel used the GRADE approach, which separates two questions that casual readers tend to blur. The first is how certain we are about the underlying evidence, rated from high down to very low. The second is how strongly that evidence points toward one action. A strong recommendation means the panel expects almost every well-informed patient to choose the same path. A conditional recommendation means the right choice genuinely depends on the person, so preferences, other health conditions, and cost should drive the decision.

An important and slightly counterintuitive point: a strong recommendation does not require high-certainty evidence. Several of the guideline's strong recommendations rest on low or very low certainty, because the panel judged that benefits, harms, cost, and feasibility all lined up decisively even when the trial data were thin. Keeping the certainty rating and the recommendation strength separate is the core skill in reading any modern guideline.

The methotrexate-anchor logic

For patients who have never taken a disease-modifying antirheumatic drug (DMARD) and have moderate-to-high disease activity, the guideline strongly recommends methotrexate monotherapy over hydroxychloroquine or sulfasalazine, and strongly recommends methotrexate monotherapy over a biologic or targeted synthetic DMARD used alone.

That second recommendation is the one people find surprising, so it is worth unpacking on the guideline's own terms. Newer biologic and targeted agents are effective, and no one disputes that. The panel's reasoning was that methotrexate delivers comparable early benefit for most patients while carrying decades of safety experience and far lower cost, and that starting with a biologic offers no reliable advantage large enough to justify going first. The comparison was also shaped by emerging safety signals around one class of targeted synthetic drugs, the JAK inhibitors, which were under active review as the guideline was finalized.

The guideline then adds conditional recommendations that keep methotrexate central even when the first attempt falls short. Methotrexate monotherapy is conditionally preferred over dual or triple conventional-DMARD combinations, and over methotrexate plus a tumor necrosis factor inhibitor, as the initial approach for many patients. Just as telling, when someone is not at target on oral methotrexate, the guideline conditionally favors optimizing methotrexate itself, by switching to the injectable subcutaneous form or splitting the dose, before adding or switching to a different DMARD. The stated rationale is explicit: even with very low certainty for these tactics, the efficacy, long-term safety, and low cost of methotrexate make it the sensible thing to maximize first.

That is what "anchor drug" means in practice. Methotrexate is not framed as a placeholder to move past quickly. It is the fixed reference point that other decisions are built around.

Treat-to-target, the strongest thread

The most robust structural idea in the guideline is treat-to-target. For patients not previously treated with biologic or targeted synthetic DMARDs, a treat-to-target approach is strongly recommended over usual care, meaning clinicians should set a defined goal of remission or low disease activity, measure it on a schedule, and adjust therapy when the goal is not met. Notably, that strong recommendation sits on low-certainty evidence, another reminder that strength and certainty are different axes.

Treat-to-target is what makes the methotrexate-first strategy safe as a starting point rather than a place to get stuck. If methotrexate is optimized and the target still is not reached, the framework is designed to escalate deliberately, not to abandon the anchor on a hunch.

Minimizing glucocorticoids

Steroids are where the guideline draws its firmest line on harm. It strongly recommends starting a conventional synthetic DMARD without longer-term glucocorticoids, defined as three months or more, rather than with them. It also conditionally advises against even short-term courses, while openly acknowledging that short bursts are frequently needed in real life to control symptoms until a DMARD takes effect. For patients relying on steroids to stay at target, the guideline conditionally favors adjusting or adding DMARDs over continuing the steroid.

The logic is cumulative-dose harm. Glucocorticoids work quickly, but sustained exposure carries real risks including infection, bone loss, and cardiovascular effects. Reading this section carefully shows a guideline treating steroids as a bridge to be crossed and left behind, rather than a foundation to stand on. This point diverges somewhat from other international recommendations, which is a useful reminder that expert panels can weigh the same evidence differently.

Reading it as a patient

Put together, the guideline offers a simple mental model. Where it speaks strongly, such as treat-to-target and methotrexate-first, it is signaling a default that fits most people. Where it speaks conditionally, which is most of the document, it is inviting a real conversation about your priorities, your other conditions, and cost. The methotrexate anchor endures for a concrete reason. Under formal grading it keeps clearing the bar of proven benefit against acceptable risk, which is a sturdier foundation than age or price. This article is educational and is not medical advice; treatment decisions belong with your own clinician.